meglitinide has been researched along with Obesity in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hamdy, O; Mitri, J | 1 |
Purnell, JQ; Weyer, C | 1 |
Ishibashi, S | 1 |
Hermansen, K; Mortensen, LS | 1 |
4 review(s) available for meglitinide and Obesity
Article | Year |
---|---|
Diabetes medications and body weight.
Topics: Abdominal Fat; Benzamides; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Obesity; Peptides; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Gain; Weight Loss | 2009 |
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Obesity; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2003 |
[Management of blood glucose--target of the management and its practice].
Topics: Benzamides; Blood Glucose; Combined Modality Therapy; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diet, Reducing; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Life Style; Obesity; Postprandial Period; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Topics: Amyloid; Benzamides; Biguanides; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Obesity; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2007 |